

Alphamab Oncology Update



- . Clinical Progress
- . Business Development
- . Management Team
- . Manufacturing

Disclaimer

This presentation has been prepared by Alphamab Oncology (the "Company") solely for use at the presentation. The information contained in this presentation has not been independently verified. No representation or warranty, expressed or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information contained herein. The information and opinions contained in this presentation are provided as of the date of this presentation or the respective cut-off date in respect of the clinical trial data, and are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. Neither the Company nor any of its affiliates, advisers or representatives accepts any liability whatsoever for any actual or consequential loss or damages howsoever arising from the provision or use of any information contained in this presentation. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such alterations, modifications or changes. This presentation contains statements that constitute forward-looking statements. These statements can be recognized by the use of words such as "expects," "plan," "will," "estimates," "projects," "intends," or words of similar meaning or intent. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward-looking statements contained in this presentation to reflect future events or circumstances. Accordingly, you should not place undue reliance on any forward-looking information. This presentation is highly confidential, is being presented solely for your information and for your use and may not be copied, reproduced or redistributed to any other person in any manner without the Company's prior written consent. Unauthorized copying, reproduction or redistribution of this presentation could be limited or prohibited by the securities laws of various jurisdictions. This presentation is for information purposes only and does not constitute an offer, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company, any of its holding companies, or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract, commitment or investment decision whatsoever. Any decision to purchase or subscribe for any securities of the Company should be made after seeking appropriate professional advice. By receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the business, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. No securities of the Company may be offered, sold or transferred within the United States or to, or for the account or benefit of U.S. persons, without registration with the United States Securities and Exchange Commission, except as pursuant to an exemption from, or in a transaction not subject to, such registration requirements. The Company has not registered and does not intend to register any securities of the Company under the U.S. Securities Act of 1933, as amended. There will be no public offering of any securities by the Company in the United States. In Hong Kong, no securities of the Company may be offered to the public unless a prospectus in connection with the offering for subscription of such shares has been formally approved by The Stock Exchange of Hong Kong Limited in accordance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) and duly registered by the Registrar of Companies in Hong Kong. The securities referred to herein have not been and will not be registered under the applicable securities laws of the People's Republic of China (the "PRC"), and may not be offered or sold within the PRC or to any national, resident or citizen of the PRC. The content of this presentation does not include and shall not be deemed as any advice (including but not limited to medical advice and investment advice). You shall be liable for any decision made by yourself based on the content of this presentation.

Clinical Progress

- Alphamab Oncology Announces Two IND Application Approvals for new therapies of KN026 from NMPA CDE**
 May 13, 2020

 Alphamab Oncology has received approvals for two IND applications for new therapies of KN026 from the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) of China. First IND application is approved to apply lyophilized dosage of KN026 for treatment of HER2-positive or HER2 expression solid tumors, including in combination with docetaxel as first-line treatment to metastatic recurrent HER2-positive or HER2 expression breast cancer. Second IND application is approved to conduct clinical trials on evaluating of the effectiveness, safety and tolerance of KN046 in combination with KN026 for HER2-positive or HER2 expression solid tumors in Phase Ib clinical study
[\[View details\]](#)
- Alphamab Oncology Announces Two IND Application Approvals for new therapies of KN046 from NMPA CDE**
 May 13, 2020

 Alphamab Oncology has received approvals for two IND applications for new therapies of KN046 from the Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) of China. First IND application is approved to conduct clinical trials on KN046 in combination with Ningetinib Tosylate for the treatment of solid tumors and blood tumors, including but not limited to the treatment of hepatocellular carcinoma (HCC). Second IND application is approved to conduct clinical trials on evaluating of the effectiveness, safety and tolerance of KN046 in combination with KN026 for HER2-positive.
[\[View details\]](#)
- Alphamab Oncology Presents Phase I Clinical Data of KN046 at the 2020 ASCO Annual Meeting**
 May 29, 2020

 Alphamab Oncology has achieved promising results for the Phase I clinical trials of KN046 (PD-L1/CTLA4 bispecific antibody) and the clinical data was presented at the ASCO Annual Meeting. KN046 has shown exciting preliminary clinical results in patients with advanced solid tumors who previously failed immuno-checkpoint inhibitor treatment. It would be further validating the efficacy of K046 as monotherapy and combos with other drugs in late stage cancer patients who have failed PD-1 treatments.
[\[View details\]](#)
- Alphamab Oncology Presents Phase I Clinical Data of KN026 at the 2020 ASCO Annual Meeting**
 May 29, 2020

 Alphamab Oncology has achieved promising results for the Phase I clinical trials of KN026 (HER2 bispecific) and the clinical data was presented at the ASCO Annual Meeting. The results of Phase I clinical trials show KN026 has encouraging anti-tumor activity in HER2-positive breast cancer patients who progressed after multiple lines of anti-HER2 treatment. Based on the favorable efficacy, clinical trials would be conducted as first line therapy in HER2-positive solid tumors as soon as possible.
[\[View details\]](#)
- Alphamab Oncology Announces Positive Clinical Data for Subcutaneous Injectable anti-PD-L1 Antibody KN035 at the 2020 ASCO Annual Meeting**
 May 29, 2020

 Alphamab Oncology's partner 3D Medicines presented Phase II clinical results of KN035 (the subcutaneous injection PD-L1 antibody) from the treatment of advanced solid tumors with microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) as monotherapy, and a combination therapy with KN035 plus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) cancer in China. The company plans to submit BLA in China by the end of 2020.
[\[View details\]](#)
- Alphamab Oncology Presents Clinical Data for KN026 at the 2020 AACR Annual Meeting**
 June 22, 2020

 Alphamab Oncology announced that the clinical study of the anti-HER2 bispecific antibody KN026 was shared at the AACR Annual Meeting. In order to determine the target concentration, researchers explored the anti-tumor activity under different KN026 exposures at various initial tumor volume and different proliferation rates based on preclinical PK-PD data and tumor growth parameters in breast cancer patients.
[\[View details\]](#)

Preliminary Clinical Data Publication Plan

Year	Month	Conference	Title
2020	November		KN046-IST-02 KN046+KN026 in HER2-positive solid tumors
2021	January	ASCO Gastrointestinal Cancers Symposium	KN046-IST-02 KN046+KN026 in HER2-positive CRC and G/GEJ
			KN046-IST-01 ESCC (CRT)
2021	January	2020 World Conference on Lung Cancer Singapore	KN046-201
			KN046-AUS-001 Thymic cancer
2021	April	AACR Cancer Therapy	KN046-203
			KN046-202
2021	June	ASCO	KN026-202
			KN026-203
2021	September	ESMO	KN046-204

Note:
 1. Essay must be accepted for submission
 2. The results of clinical trials can not be predicted
 3. 2020 WJCLC conference is postponed to 2021, January


Preliminary Clinical Development Plan

Program	Key indication	Preclinical	Phase I	Phase II	Phase III	BLA
KN046 KN026	★ Thymic carcinoma		Registration trial (in preparation)			
	NPC		Registration trial (in preparation)			
	★ NSCLC, 1L (KN046+CT)		Registration trial (in preparation)			
KN046 (PD-L1/CTLA-4)	NSCLC, PD1/PD-L1 ref/rel (KN046 or KN046+TKI)					
	NSCLC, stage III (KN046+RT)					
	TNBC, 1L (KN046+nab-paclitaxel)					
	TNBC, neoadjuvant					
	MSI-H/dMMR CRC, neoadjuvant					
	HCC, 1L (KN046+TKIs)					
	ESCC, 1L (KN046+CT, KN046+CRT)					
KN026 (HER2 bispecific)	★ HER2-positive MBC, 1L (KN026+docetaxel)		Registration trial (in preparation)			
	HER2/HR-positive MBC, late line (KN026+CDK4/6+fulvestrant)					
	HER2-low MBC & mGC/GEJ, late line (KN026)					
KN026+KN046	★ HER2-positive mGC/GEJ (KN026+KN046)					
	HER2-positive solid tumors (KN026+KN046)					

★ | Pivotal trial to be initiated in the near term

Business Development Strategy


HER2-negative solid tumors KN046 & KN046-based combination



Do-Youn Oh 2019

- Notes:
 1. Herceptin's label only covers Her-2 High, about 25% of breast cancer patients. While total Her-2 High, Midium and Low is about 80% of patients
 2. Herceptin's label only covers Her-2 High, about 10-18% of gastric cancer patients. While total Her-2 High, Midium and Low is about 40% of patients

HER2-positive, HER2-int/low and HER2-mutation KN026-based combination & KN026+KN046



Business Development

KN026 Update

- Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance® (palbociclib)**
 March 27, 2020

 Alphamab Oncology has entered a clinical supply agreement with Pfizer Inc. to advance a clinical study to investigate KN026 in combination with Ibrance® (palbociclib), an oral CDK4/6 inhibitor, in patients with previously-treated locally advanced and/or metastatic HER2-positive breast cancer. Jianguo Alphamab, as the study sponsor, will oversee and run the trial, and Pfizer will supply palbociclib.
[\[View details\]](#)
- Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer**
 June 09, 2020

 Alphamab Oncology signed an agreement with Sanofi (China) Investment Co., Ltd to establish strategic collaboration to advance clinical studies to investigate KN026 in combination with Taxotere® (Docetaxel) in HER2+ breast cancer. This is KN026's second collaboration deal with major global pharma companies.
[\[View details\]](#)

KN046 Update

- Alphamab Oncology and InxMed Announce Partnership to Develop Combination Therapy of KN046 and IN10018**
 May 23, 2020

 Alphamab Oncology has entered a partnership agreement with InxMed (Shanghai) Co., Ltd., to jointly develop the combination therapy of PD-L1 / CTLA-4 bispecific antibody KN046 and focal adhesion kinase inhibitor IN10018. This collaboration will first evaluate the safety, tolerability, and efficacy of the combination of KN046 and IN10018 in patients with pancreatic cancer.
[\[View details\]](#)
- Alphamab Oncology and Sunshine Lake expand partnership to accelerate the development of the combination therapy of KN046 and CT053**
 May 28, 2020

 Alphamab Oncology announced it has expanded partnership with Sunshine Lake Pharma Co., Ltd. to lead and executed to accelerate the clinical development and commercialization of the combination therapy of PD-L1 / CTLA-4 bispecific antibody (KN046) and Ningetinib Tolueneulfonate (CT053) in China.
[\[View details\]](#)
- Alphamab Oncology and Sinovent Announce Partnership to Co-Develop the Combination Therapy of KN046 and XNW7201**
 June 19, 2020

 Alphamab Oncology has entered a partnership agreement with Sinovent, to jointly develop the combination therapy of PD-L1 / CTLA-4 bispecific antibody KN046 and small-molecule inhibitor XNW7201 in oncology indications.
[\[View details\]](#)
- Alphamab Oncology and Kintor Pharmaceutical Announce Partnership to Develop Combination Therapy of KN046 and GT90001**
 July 30, 2020

 Alphamab Oncology has entered a partnership agreement with Kintor Pharmaceutical Limited ("Kintor Pharmaceutical", stock code 9939.HK), to jointly develop the combination therapy of KN046 and ALK-1 monoclonal antibody GT90001 in hepatocellular carcinoma (HCC).
[\[View details\]](#)

Other opportunities

- Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody**
 June 10, 2020

 Alphamab Oncology has entered a partnership agreement with Institut Pasteur of Shanghai, Chinese Academy of Sciences on the co-development, manufacturing and commercialization of Corona Virus Disease 2019 (COVID-19) worldwide.
[\[View details\]](#)

Management Team Update

Vice President, Regulatory Affairs
 Li Wan, Ph.D., RAC

- Over fifteen years of industry experience in global regulatory affairs and project management
- Served various positions in a number of pharmaceutical companies including Pfizer and Novartis in the US, Luye Pharma
- Led many global IND/CTA/NDA submissions and obtained approvals for small molecules and biologics products, with expert knowledge of the FDA, EMA, NMPA, PMDA, and ICH regulations
- Doctoral degree in Pharmaceutical Science from Rutgers University, MS/BS degrees in Biology from Nanjing University



Vice President, Quality
 Weidong Ma

- 25 years of extensive experience in Quality Management
- Served various positions in a number of pharmaceutical companies including WuXi Biologics, Amgen China and Roche Shanghai
- Led team to pass several audits from FDA, EMA and NMPA
- B.S in Chemistry from Shanghai Normal University



Manufacturing Update

Jianguo Alphamab's New Manufacturing Facilities' Phase I production lines Have Received "Drug Production License"

July 06, 2020
 Alphamab Oncology announced the Phase I 2x2,000L production lines of its new manufacturing facilities which has a designed total capacity over 30,000L and is located at No. 175 Fangzhou Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, has obtained "Drug Production License" by Jiangsu Provincial Drug Administration.
[\[View details\]](#)



About Alphamab Oncology

We are a leading clinical-stage biopharmaceutical company in China with a fully-integrated proprietary biologics platform in bispecifics and protein engineering, delivering world-class innovative therapeutic biologics to cancer patients globally.

Proven Team	Global Rights	Innovation	Integrated Platform
<ul style="list-style-type: none"> Founded by a visionary scientist who has made contributions to over 100 patents and patent applications since 2011 Strong in-house R&D contributed to the CMC processes of many biosimilar BLAs filed in China since 2017 	<ul style="list-style-type: none"> All in-house developed candidates Global rights (IP, Commercial) Ongoing Australia/China and imminent US trials for KN046 Ongoing US/China trials for KN026 Ongoing US/Japan/China trials for KN035 	<ul style="list-style-type: none"> All in-house developed proprietary sdAb, CRIB and CRAMP Robust first-in-class global next-generation product pipeline 	<ul style="list-style-type: none"> Fully developed platform consisting of drug discovery, development and manufacturing

Product Overview

KN035 Subcutaneous PD-L1	KN046 Dual blockade of PD-L1 and CTLA-4	KN026 Dual blockade of HER2 domain II and IV	KN019 A safe option for autoimmune diseases	4 pre-clinical bispecific candidates
Subcutaneous PD-L1 for maintenance therapy	Enable earlier lines of therapies for improved efficacy and safety	Potential for all settings of HER2 aberration Synergy with KN046 through immune modulation	Supplement to immunotherapies for AE management	Target both proven and innovative pathways
				<ul style="list-style-type: none"> KN052 KN053 KN055 KN058